
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Neurol., 23 March 2022
Sec. Multiple Sclerosis and Neuroimmunology
Volume 13 - 2022 | https://doi.org/10.3389/fneur.2022.888513
This article is a correction to:
Case Report: A False Negative Case of Anti-Yo Paraneoplastic Myelopathy
A Corrigendum on
Case Report: A False Negative Case of Anti-Yo Paraneoplastic Myelopathy
by Bartley, C. M., Parikshak, N. N., Ngo, T. T., Alexander, J. A., Zorn, K. C., Alvarenga, B. D., Kang, M. K., Pedriali, M., Pleasure, S. J., and Wilson, M. R. (2021). Front. Neurol. 12:728700. doi: 10.3389/fneur.2021.728700
An author name was incorrectly spelled as Bonny A. Alvarenga. The correct spelling is Bonny D. Alvarenga.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: paraneoplastic neurologic disease, myelopathy, anti-Yo antibodies, phage display, breast cancer, CDR2L
Citation: Bartley CM, Parikshak NN, Ngo TT, Alexander JA, Zorn KC, Alvarenga BD, Kang MK, Pedriali M, Pleasure SJ and Wilson MR (2022) Corrigendum: Case Report: A False Negative Case of Anti-Yo Paraneoplastic Myelopathy. Front. Neurol. 13:888513. doi: 10.3389/fneur.2022.888513
Received: 02 March 2022; Accepted: 04 March 2022;
Published: 23 March 2022.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Bartley, Parikshak, Ngo, Alexander, Zorn, Alvarenga, Kang, Pedriali, Pleasure and Wilson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Michael R. Wilson, bWljaGFlbC53aWxzb25AdWNzZi5lZHU=
†These authors have contributed equally to this work
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.